Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00968851 · ClinicalTrials.gov registry record · Phase 2

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

A Phase 2 study of Schizophrenia and Cognition, sponsored by FORUM Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
317
Enrollment target
20
Study locations

NCT00968851 is a Phase 2 study of Schizophrenia and Cognition that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 317 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00968851, a Phase 2 study of Schizophrenia and Cognition, has completed, sponsored by FORUM Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
317 participants
Enrollment target
20
Study locations

Study Summary

This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical anti-psychotic therapy. In addition, behavioral and psychotic symptoms will be evaluated.

Conditions Studied

Schizophrenia Cognition Central Nervous System Diseases

Interventions

  • DRUG Placebo
  • DRUG EVP-6124

Study Locations (20)

Other

  • - Arkhangelsk
  • - Kazan'
  • - Moscow
  • - Moscow
  • - Saint Petersburg
  • - Stavropol

California

  • Intergrated Medical and Behavioral Associates - Glendale
  • Excell Research - Oceanside
  • University of California, San Diego - San Diego
  • Affiliated Research Institute - San Diego
  • Schuster Medical Research Institute - Sherman Oaks

Illinois

  • Uptown Research Institute - Chicago
  • Alexian Brothers Behavioral Health - Hoffman Estates

Texas

  • FutureSearch Clinical Trials, L.P. - Austin
  • InSite Clinical Research - DeSoto

Florida

  • Scientific Clinical Research, Inc. - North Miami

Maryland

  • CBH Health, LLC - Rockville

New Jersey

  • CRI Worldwide - Willingboro

South Carolina

  • Carolina Clinical Trials, Inc. - Charleston

Trial Details

FieldValue
Enrollment Target 317 participants
Start Date 2009-12
Est. Completion 2011-03
Phase Phase 2

Sponsor

FORUM Pharmaceuticals

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00968851

The ClinicalTrials.gov registry entry for NCT00968851 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (45% higher). The listed sponsor is FORUM Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00968851 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT00968851 about?

NCT00968851 is a clinical study titled "Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia". This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical anti-psychotic therapy. In addition, behavioral and psychotic symptoms will b...

What is the current status of trial NCT00968851?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2009-12. Estimated completion is 2011-03.

What conditions does trial NCT00968851 study?

This clinical trial studies the following conditions: Schizophrenia, Cognition, Central Nervous System Diseases.

What interventions are being tested in trial NCT00968851?

The interventions under investigation include: Placebo (DRUG), EVP-6124 (DRUG).

Who is sponsoring clinical trial NCT00968851?

This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00968851 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Cognition

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.